Renalytix (RENX) – PRNewswire
-
Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
-
Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards
-
Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in the Joint Ventures Category
-
FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
-
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
-
NKF and RenalytixAI Partner to Improve Management of Early Stage Kidney Disease
-
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
-
EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe
-
CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits
-
RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update
-
RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market
-
RenalytixAI Announces Partnership with America's Choice Provider Network for Coverage Expansion
-
RenalytixAI Announces KidneyIntelX Validation Study Accepted for Publication in American Society of Nephrology Journal Kidney360
-
RenalytixAI Announces Partnership with the University of Michigan to Extend KidneyIntelX™ Use to Broad CKD Populations and Data Sharing Agreement with a Top Ten Global Pharmaceutical Company
-
RenalytixAI Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual-listing and Global Offering
-
KidneyIntelX™ Receives New York State Approval to Commence Commercial Testing
-
Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test
-
Renalytix AI Announces Proposed Dual-listing on Nasdaq
-
RenalytixAI Utah Commercial Laboratory Facility Achieves ISO 13485 Certification
-
KidneyIntelX™ to Predict Major Adverse Kidney Events in COVID-19 Patients
-
RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify
-
RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference
-
Medicare Sets National Price for KidneyIntelX™
-
RenalytixAI Partners with Capital District Physicians' Health Plan, Inc. on KidneyIntelX™
-
Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board
-
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer
Back to RENX Stock Lookup